Keywords COVID-19 vaccine multiple myeloma SARS-CoV-2 hematology oncology COVID-19 mRNA vaccines are highly efficacious in preventing COVID-19 morbidity and mortality in phase 3 clinical studies as well as in real-world settings. Emerging evidence suggests that some individuals with underlying comorbidities may mount suboptimal antibody responses to SARS-CoV-2 immunization (; Monin et al., 2021 Monin L. Laing A.G. Muñoz-Ruiz M. McKenzie D.R. Del Molino Del Barrio I. Alaguthurai T. Domingo-Vila C.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile